Genicular Nerve Block for Knee Osteoarthritis

A genicular nerve block is an injection of local anesthetic around the sensory nerves that transmit pain signals from an arthritic knee joint to the brain, and it can provide meaningful short-term relief for people with knee osteoarthritis. The procedure often serves a dual purpose: it reduces pain on its own and acts as a screening test before a longer-lasting treatment called radiofrequency ablation, which uses heat to disable those same nerves for months at a time. A meta-analysis of randomized controlled trials found that genicular nerve interventions significantly reduced pain and improved knee function compared with other treatments, though the story of who benefits most and how long relief lasts has more layers than that summary suggests.

Which Nerves Are Involved

The knee joint capsule is wrapped in a network of small sensory nerve branches. Cadaveric and imaging studies have mapped them in detail, identifying at least seven distinct nerves that supply sensation to the front of the knee. These include the superior medial, superior lateral, and inferior medial genicular nerves, along with branches from the nerves supplying the quadriceps muscles and a recurrent fibular nerve on the outer side.

The three nerves most commonly targeted during a genicular nerve block or ablation are the superior medial genicular nerve, the superior lateral genicular nerve, and the inferior medial genicular nerve. An MRI-based study found that standard bony landmark targets lined up well with these nerves: the superior lateral nerve was at or above the target point in 92% of knees, the superior medial nerve in 88%, and the inferior medial nerve in 100%.¹ That consistency is reassuring, but it also means roughly one in ten patients may have anatomical variation that puts one of those nerves slightly out of reach of a standard needle placement. Newer protocols are expanding the number of nerves targeted, adding branches like the nerve to vastus intermedius, to improve coverage.

The articular branches of these nerves run along the periosteum, the thin tissue layer covering the bone, which makes them accessible to a needle placed under image guidance near specific bony landmarks around the knee.² The fact that these are purely sensory nerves is important: blocking or ablating them does not weaken the muscles around the knee, because the motor nerve branches take separate paths.

How the Block and Ablation Work

A genicular nerve block itself is straightforward. Under ultrasound or fluoroscopic guidance, a clinician inserts a needle to each target site and injects a small volume of local anesthetic. The effect is temporary, lasting hours to weeks depending on the anesthetic used. The block’s main clinical job is often to confirm that genicular nerve pain pathways are responsible for the patient’s symptoms before committing to a more involved ablation procedure.

Radiofrequency ablation (RFA) takes the concept further. Instead of numbing the nerve temporarily, a cannula is placed at each target site and an electrical current heats the tip to between 70°C and 80°C for 60 to 90 seconds. This denatures the proteins in the nerve tissue, interrupting its ability to transmit pain signals.³ Cooled RFA uses internally cooled electrodes that allow a larger zone of tissue disruption while keeping surface temperatures lower, which can be an advantage when the nerve’s exact location is uncertain. Pulsed radiofrequency is a gentler variant that delivers intermittent energy bursts without reaching tissue-destructive temperatures, aiming to modulate nerve signaling rather than destroy it outright.

Does a Diagnostic Block Actually Predict Ablation Success?

This is one of the more debated questions in the field. The logic seems sound: inject local anesthetic first, and if the patient gets significant relief, they are a good candidate for ablation. In practice, the evidence is muddier than you might expect.

A prospective randomized trial found that patients who went straight to cooled RFA without a prior diagnostic block did just as well as those who were screened first. Roughly 59% of the block-screened group and 64% of the unscreened group achieved at least 50% pain relief at six months, with no statistically significant difference.⁴ Another study painted a similar picture: 81% of patients reported strong pain relief after a diagnostic block, but only 35% went on to achieve at least 50% pain reduction from the subsequent RFA, suggesting the block was overly optimistic as a predictor.⁵

That said, at least one study found that a positive diagnostic block with a 50% pain relief threshold was a significant predictor of ablation success when other variables were accounted for, including opioid use and depression.⁶ The picture that emerges is that diagnostic blocks are helpful but far from foolproof. A positive block does not guarantee ablation will work, and skipping the block does not doom the ablation to failure. Clinicians still use diagnostic blocks widely, but their predictive value is more modest than early enthusiasm suggested.

Pain Relief and Functional Gains

A systematic review and meta-analysis of randomized controlled trials found that genicular nerve interventions significantly reduced pain compared with control treatments, with the most pronounced effect at two weeks and continued functional improvement visible at 12 weeks.⁷ A separate systematic review focused specifically on ablation reported that average pain scores dropped from about 8 out of 10 before the procedure to roughly 2 out of 10 at three months, with some gradual rise back toward 4 out of 10 by one year.⁸

Functional outcomes go beyond pain scores. A study tracking physical performance after ultrasound-guided genicular nerve RFA found that a step test improved significantly over 12 weeks of follow-up. Importantly, there were no declines in standing balance, quadriceps muscle strength, knee proprioception, or walking endurance.⁹ This confirms the theoretical advantage of targeting purely sensory nerves: you reduce pain without undermining the motor function people need for walking, climbing stairs, and getting out of chairs.

How It Compares to Injections

Most people with knee osteoarthritis have already tried corticosteroid or hyaluronic acid injections by the time genicular nerve procedures are on the table. A multicenter randomized trial compared cooled RFA targeting three genicular nerves against intra-articular corticosteroid injection. At six months, 74% of the RFA group reported at least 50% pain relief, compared with just 16% in the corticosteroid group. At 12 months, 65% of available RFA patients still met that threshold, though more than half had been lost to follow-up or had undergone additional knee procedures by that point. A separate trial comparing cooled RFA against hyaluronic acid injections found a similar pattern: 71% versus 38% achieving meaningful pain relief at six months.¹⁰

Those are striking numbers, but the open-label design of those trials deserves a mention. Participants knew which treatment they received, which can inflate perceived benefit in the more invasive group. Still, the size of the gap between RFA and injections is large enough that most pain specialists consider RFA the stronger intervention for patients who have exhausted simpler options.

Conventional Versus Cooled Radiofrequency

You will see clinics offering either conventional (thermal) RFA or cooled RFA, and you might wonder whether one is better. Two studies that directly compared the two techniques found no statistically significant difference in pain relief or complication rates.¹¹ ¹² Both approaches produced significant improvements in pain and function scores at follow-up. The theoretical advantage of cooled RFA is a larger lesion size, which may help compensate for slight inaccuracies in needle placement. In practice, neither has proven clearly superior, so the choice often comes down to what equipment the clinic has and the treating physician’s experience.

Continuous neuroablative RFA has shown some advantages over pulsed radiofrequency neuromodulation in head-to-head comparison. One randomized trial found that continuous RFA produced greater and longer-lasting pain relief and a larger reduction in analgesic use compared with the pulsed technique.¹³ Pulsed RF may still have a role for patients who are not good candidates for thermal ablation, but the evidence currently favors the continuous thermal approach for osteoarthritis pain.

Reducing Pain Medication

One of the less-discussed benefits is the impact on medication use. A case series of patients who underwent cooled RFA found that all participants either reduced or maintained their opioid and analgesic use after the procedure.¹⁴ A pilot study of an expanded genicular nerve ablation protocol reported that among three patients taking daily opioids before the procedure, two stopped entirely and the third switched to a weaker agent.¹⁵ These are small numbers, but the direction is consistent: when knee pain drops substantially, the need for pain medication tends to follow. For patients worried about long-term opioid use or the gastrointestinal side effects of anti-inflammatory drugs, this is a practical advantage worth considering.

Safety and Side Effects

Genicular nerve procedures have a strong safety profile. A systematic review of randomized controlled trials and retrospective studies found that the most common complication was temporary local pain at the injection or ablation site. Other reported side effects included minor bruising, swelling, and decreased skin sensation near the procedure site. All complications were transient, resolving within two weeks, and there was no significant difference in complication rates between genicular nerve blocks and ablation.¹⁶ A separate review confirmed that no serious procedure-related adverse events were reported, with minor complications described as infrequent and self-limiting.¹⁷

One anatomical consideration that comes up in precision planning is the proximity of blood vessels to the nerve targets. A study examining sex- and side-specific variations found that nearly half of the superior lateral genicular nerves had no nearby vascular supply at the standard target point, which actually simplifies targeting with ultrasound.¹⁸ Where vessels are present, image guidance helps the clinician avoid them. The upshot is that serious vascular injury during these procedures is essentially unreported in the literature.

Ultrasound Versus Fluoroscopy for Guidance

Both ultrasound and fluoroscopy (real-time X-ray) are used to guide needle placement. A prospective randomized trial comparing the two found no differences in pain relief, functional improvement, or complication rates.¹⁹ The practical takeaway: either method works. Ultrasound has the advantage of avoiding radiation exposure, being portable, and allowing real-time visualization of soft tissues like blood vessels. Fluoroscopy provides clear bony landmark identification that some practitioners prefer. Both techniques were effective in a separate study of genicular nerve blocks for knee osteoarthritis, confirming that the modality of guidance matters less than the skill of the person holding the probe or operating the machine.²⁰

Why the Relief Does Not Last Forever

Radiofrequency ablation disrupts nerve fibers but does not destroy the entire nerve structure. The injury is classified as a third-degree axonotmesis: the inner nerve fibers and their insulation are damaged, but the outer scaffolding of the nerve stays largely intact. This scaffolding provides a pathway along which the nerve can slowly regenerate. In addition to outright regrowth, the nerve can regain function through remyelination and collateral sprouting from surviving fibers nearby.²¹ This is why pain tends to creep back months after an ablation.

The good news is that the procedure can be repeated. It has been demonstrated to be safe for repeat administration in patients who responded well the first time.²² For many patients, this creates a cycle of treatment: ablation provides months of relief, pain gradually returns as the nerve recovers, and repeat ablation restores the benefit. Whether successive treatments maintain the same degree of relief or show diminishing returns is an active area of research, but early data suggests the procedure can be repeated effectively.

Who Is a Good Candidate

Genicular nerve procedures fit a specific niche in the treatment landscape. They are particularly relevant for people who have moderate to severe knee osteoarthritis and have not gotten adequate relief from exercise, physical therapy, oral medications, and intra-articular injections. They are also valuable for patients who are not candidates for total knee replacement due to medical comorbidities. A systematic review specifically noted that rising rates of obesity and diabetes have increased the number of patients who would benefit from joint replacement but cannot safely undergo surgery, making genicular nerve ablation an appealing alternative.²³

Depression and opioid use appear to influence outcomes. The study that identified predictors of ablation success found that patients without current opioid use were roughly 2.7 times more likely to respond well, while those with depression were significantly less likely to succeed.²⁴ This does not mean patients with depression or opioid use should be excluded, but it suggests the procedure works best as part of a broader pain management plan that addresses psychological and pharmacological factors alongside the nerve intervention.

Relief After Total Knee Replacement

Somewhere between 10% and 34% of people who undergo total knee arthroplasty end up with persistent pain afterward. This is an area where genicular nerve procedures are gaining traction. The earliest report of using genicular nerve RFA after a knee replacement was a single case demonstrating improved pain and function.²⁵ Since then, the evidence base has expanded. A systematic review identified 11 studies covering 265 patients with post-replacement knee pain treated with various types of genicular nerve radiofrequency procedures.²⁶

A direct comparison study found that RFA produced comparable pain relief and functional improvement in osteoarthritis patients and post-replacement patients, with an overall success rate of about 81% at three months and 56% at six months. There was no statistically significant difference between the two groups at any time point.²⁷ For someone living with unexplained pain after a knee replacement, where the hardware looks fine on imaging and infection has been ruled out, genicular nerve ablation is one of the few interventions with real evidence behind it.

Cost-Effectiveness

Procedures involving specialized radiofrequency equipment are not cheap, and insurers want to know whether the cost is justified. A formal cost-effectiveness analysis compared cooled RFA against intra-articular hyaluronic acid injections and found that cooled RFA was cost-effective at a threshold of $100,000 per quality-adjusted life year, which is the standard benchmark used in the United States.²⁸ Because the relief from ablation lasts many months, the cost per month of benefit compares favorably with injections that need repeating every few months. For patients considering the procedure, insurance coverage has been expanding, though it varies by plan and often requires documentation of failed conservative treatments.

Chemical Neurolysis as an Alternative

Radiofrequency equipment is not available everywhere, and some clinicians have explored chemical alternatives. A case series reported successful use of phenol injected at the genicular nerve targets as a form of chemical neurolysis. Patients in the series experienced 75% to 100% immediate pain relief that was sustained at follow-up. Potential advantages of this approach include lower cost, simpler logistics, and the ability to cover a wider area of nerve tissue depending on the volume injected. Phenol may also cause less post-procedure nerve irritation compared with alcohol-based neurolysis.²⁹ Chemical neurolysis remains far less studied than RFA, but it offers a potential option in resource-limited settings or for patients who cannot access radiofrequency-equipped pain clinics.